Genetic imaging consortium for addiction medicine: From neuroimaging to genes.
Genetic imaging consortium for addiction medicine: From neuroimaging to genes.
复制标题
DOI:
10.1016/bs.pbr.2015.07.026
复制
发表时间:
2016
影响因子:
--
通讯作者:
Conrod P
中科院分区:
文献类型:
--
作者:
Mackey S;Kan KJ;Chaarani B;Alia-Klein N;Batalla A;Brooks S;Cousijn J;Dagher A;de Ruiter M;Desrivieres S;Feldstein Ewing SW;Goldstein RZ;Goudriaan AE;Heitzeg MM;Hutchison K;Li CS;London ED;Lorenzetti V;Luijten M;Martin-Santos R;Morales AM;Paulus MP;Paus T;Pearlson G;Schluter R;Momenan R;Schmaal L;Schumann G;Sinha R;Sjoerds Z;Stein DJ;Stein EA;Solowij N;Tapert S;Uhlmann A;Veltman D;van Holst R;Walter H;Wright MJ;Yucel M;Yurgelun-Todd D;Hibar DP;Jahanshad N;Thompson PM;Glahn DC;Garavan H;Conrod P
Since the sample size of a typical neuroimaging study lacks sufficient statistical power to explore unknown genomic associations with brain phenotypes, several international genetic imaging consortia have been organized in recent years to pool data across sites. The challenges and achievements of these consortia are considered here with the goal of leveraging these resources to study addiction. The authors of this review have joined together to form an Addiction working group within the framework of the ENIGMA project, a meta-analytic approach to multisite genetic imaging data. Collectively, the Addiction working group possesses neuroimaging and genomic data obtained from over 10,000 subjects. The deadline for contributing data to the first round of analyses occurred at the beginning of May 2015. The studies performed on this data should significantly impact our understanding of the genetic and neurobiological basis of addiction.